文献速递免疫规划卫生政策与健康促进

日本65岁及以上成人接种重组带状疱疹疫苗与减毒活疫苗的成本效果分析

Cost-effectiveness of Recombinant Zoster Vaccine (RZV) and Varicella Vaccine Live (VVL) against herpes zoster and post-herpetic neuralgia among adults aged 65 and over in Japan.
PubMed 文献 · Vaccine · 2019-05-29

该研究采用马尔可夫模型,从支付方视角评估日本65岁及以上人群接种VVL或RZV预防带状疱疹及带状疱疹后神经痛的成本效果。在VVL每剂8000日元、2剂RZV共30000日元的接种成本下,各年龄策略的ICER值显示VVL策略为2,633,587至3,434,267日元/QALY,RZV策略为5,262,227至6,278,557日元/QALY。结论认为两种疫苗在相应年龄组均具成本效果,但最优策略取决于支付意愿阈值。

要点

  • VVL策略ICER为2,633,587至3,434,267日元/QALY,RZV策略为5,262,227至6,278,557日元/QALY。
  • 支付意愿阈值为3,000,000日元/QALY时,65-84岁VVL策略可接受性90.7%,RZV策略8.8%。
  • 支付意愿阈值为10,000,000日元/QALY时,65-84岁VVL策略可接受性11.9%,RZV策略88.1%。

核心结论

  • 在日本,对65-84岁、70-84岁、75-84岁、80-84岁人群接种VVL或RZV预防带状疱疹相关疾病,从支付方视角看均具成本效果。
  • 仅65-84岁VVL策略和65-84岁RZV策略在引入带状疱疹免疫规划时应予考虑。
  • 最优策略随支付意愿阈值变化而变化。

研究设计与样本

  • 研究采用马尔可夫模型进行成本效果分析,从支付方视角评估免疫规划效率。
  • 设置8种策略,分别为65-84岁、70-84岁、75-84岁、80-84岁接种VVL或RZV。
  • 计算与仅治愈护理情景相比的增量成本效果比(ICER)。
  • 随访健康状态包括急性带状疱疹后康复、带状疱疹后神经痛后康复、带状疱疹/PHN后状态、带状疱疹复发和一般死亡。

主要发现

  • 在VVL每剂8000日元(73美元)、2剂RZV共30000日元(273美元)的接种成本下,VVL策略ICER为2,633,587日元/US$23,942(80-84岁)至3,434,267日元/US$31,221(65-84岁)/QALY gained。
  • RZV策略ICER为5,262,227日元/US$47,838(80-84岁)至6,278,557日元/US$57,078(65-84岁)/QALY gained。
  • 概率敏感性分析的成本效果可接受性曲线显示,阈值为3,000,000日元/US$27,273/QALY时,65-84岁VVL策略和65-84岁RZV策略的可接受性分别为90.7%和8.8%。
  • 阈值为5,000,000日元/US$45,455/QALY时,上述两策略可接受性分别为56.2%和43.8%。
  • 阈值为10,000,000日元/US$90,909/QALY时,上述两策略可接受性分别为11.9%和88.1%。

关键数值与推荐

  • VVL接种成本为每剂8000日元(73美元)。
  • 2剂RZV接种成本为30000日元(273美元)。
  • VVL策略ICER范围:2,633,587至3,434,267日元/QALY gained。
  • RZV策略ICER范围:5,262,227至6,278,557日元/QALY gained。

临床怎么用

  • 在支付方视角下,可根据当地支付意愿阈值选择VVL或RZV接种策略。
  • 当支付意愿阈值较低时,65-84岁VVL策略更具成本效果优势。
  • 当支付意愿阈值较高时,65-84岁RZV策略更具成本效果优势。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The approval of the extended use of 1-dose varicella vaccine (VVL) in adults aged 50 and older against herpes zoster (HZ) in 2016 and the 2-dose recombinant zoster vaccine (RZV) in 2018 raised the need to evaluate the value for money between these two vaccines. METHODS: We conducted a cost-effectiveness analysis with Markov modelling to evaluate the efficiency of the immunisation programmes from payer's perspective. Eight strategies with different ages to receive VVL or RZV were set, namely: 65-84 year old (y.o.), 70-84 y.o., 75-84 y.o., and 80-84 y.o. VVL- or RZV-strategy. Incremental cost-effectiveness ratios (ICERs) compared with curative care scenario were calculated. The health statuses following the target cohort were as follows: acute HZ followed by recovery, post-herpetic neuralgia followed by recovery, post HZ/PHN, recurrence of HZ, and general death. RESULTS: At the vaccination cost ¥8000 (US$73) for 1-dose ZVL and ¥30,000 (US$273) for 2-dose RZV, ICERs ranged from ¥2,633,587/US$23,942 (age 80-84 y.o.) to ¥3,434,267 or US$31,221 (age 65-84 y.o.)/QALY gained for VVL-strategies; from ¥5,262,227 or US$47,838 (age 80-84 y.o.) to ¥6,278,557 or US$57,078/QALY gained (age 65-84 y.o.) for RZV-strategies. Cost-effectiveness acceptability curves derived from probabilistic sensitivity analyses showed that if the cost-effective threshold was at ¥3,000,000 or US$27,273/QALY, the acceptability was 90.7% and 8.8% for 65-84 VVL-strategy and 65-84 RZV-strategy, respectively; if at ¥5,000,000 or US$45,455/QALY, 56.2% and 43.8%, and if at ¥10,000,000 or US$90,909/QALY 11.9% and 88.1%, respectively. CONCLUSION: Vaccinating individuals aged 65-84 y.o., 70-84 y.o., 75-84 y.o., 80-84 y.o. with VVL or RZV to prevent HZ-associated disease in Japan can be cost-effective from payer's perspective, with vaccination costs at ¥8,000 per shot for VVL, ¥30,000 for 2-dose RZV. While the results suggesting that only 65-84 VVL-strategy and 65-84 RZV strategy should be considered when introducing HZ immunisation programme. The optimal strategy varies depending on the willingness-to-pay threshold.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Hoshi SL, Seposo X, Shono A, et al. Cost-effectiveness of Recombinant Zoster Vaccine (RZV) and Varicella Vaccine Live (VVL) against herpes zoster and post-herpetic neuralgia among adults aged 65 and over in Japan. Vaccine. 2019. PMID: 31153691. doi:10.1016/j.vaccine.2019.05.006

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。